Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 5/2011

01-10-2011 | Laboratory Investigation

Hepatic Arterial Embolization with Doxorubicin-Loaded Superabsorbent Polymer Microspheres in a Rabbit Liver Tumor Model

Authors: Sanjay Gupta, Kenneth C. Wright, Joe Ensor, Carolyn S. Van Pelt, Katherine A. Dixon, Vikas Kundra

Published in: CardioVascular and Interventional Radiology | Issue 5/2011

Login to get access

Abstract

Objectives

The pharmacokinetic profile after hepatic arterial embolization with superabsorbent microspheres (QuadraSpheres) loaded with doxorubicin was studied.

Methods

Rabbits with hepatic VX2 tumors were treated with intra-arterial administration of QuadraSpheres loaded with doxorubicin, or transarterial chemoembolization (TACE) using doxorubicin, Lipiodol and Embospheres, or hepatic arterial infusion (HAI) of doxorubicin. Tumor specimens were evaluated by fluorescence microscopy, and plasma and tumor concentrations of doxorubicin were measured.

Results

The peak plasma concentration of doxorubicin was lower in the QuadraSphere group (309.9 ng/ml) than in the HAI (673.4 ng/ml) or TACE (360.5 ng/ml) groups, suggesting higher tumor retention in the QuadraSphere group. Intratumoral doxorubicin levels declined to negligible levels at 1 and 3 days after treatment, respectively, in the HAI and TACE groups. In the QuadraSphere groups, intratumoral doxorubicin level declined after day 1, but was still detectable at 14 days after treatment and was higher than that in the other groups at 1, 3, and 7 days. Intratumoral doxorubicin fluorescence was detected at all time points in the QuadraSphere group, but only at 1 day after treatment in the TACE group.

Conclusions

Hepatic arterial administration of doxorubicin-loaded QuadraSpheres enables the sustained release of doxorubicin to hepatic tumors.
Literature
1.
Dodd GD 3rd, Soulen MC, Kane RA et al (2000) Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 20:9–27PubMed
2.
Liem MS, Poon RT, Lo CM et al (2005) Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 11:4465–4471PubMed
3.
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRef
4.
Maataoui A, Qian J, Vossoughi D et al (2005) Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 15:127–133PubMedCrossRef
5.
Martin M, Tarara D, Wu YM et al (1996) Intrahepatic arterial chemoembolization for hepatocellular carcinoma and metastatic neuroendocrine tumors in the era of liver transplantation. Am Surg 62:724–732PubMed
6.
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429–442PubMedCrossRef
7.
Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739PubMedCrossRef
8.
Dhanasekaran R, Kooby DA, Staley CA et al (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 101:476–480PubMed
9.
Eyol E, Boleij A, Taylor RR et al (2008) Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis 25:273–282PubMedCrossRef
10.
Hong K, Khwaja A, Liapi E et al (2006) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12:2563–2567PubMedCrossRef
11.
Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476PubMedCrossRef
12.
Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41-52
13.
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342PubMedCrossRef
14.
Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17:1335–1343PubMedCrossRef
15.
Taylor RR, Tang Y, Gonzalez MV et al (2007) Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30:7–14PubMedCrossRef
16.
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481PubMedCrossRef
17.
Egorin MJ (1998) Overview of recent topics in clinical pharmacology of anticancer agents. Cancer Chemother Pharmacol 42(Suppl):S22–S30PubMedCrossRef
18.
Emerich DF, Snodgrass P, Lafreniere D et al (2002) Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 19:1052–1060PubMedCrossRef
19.
Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104:1645–1653PubMedCrossRef
20.
Khankan AA, Osuga K, Hori S et al (2004) Embolic effects of superabsorbent polymer microspheres in rabbit renal model: comparison with tris-acryl gelatin microspheres and polyvinyl alcohol. Radiat Med 22:384–390PubMed
21.
Bilbao JI, de Luis E, Garcia de Jalon JA et al (2008) Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 19:1625–1638PubMedCrossRef
22.
de Luis E, Bilbao JI, de Ciercoles JA et al (2008) In vivo evaluation of a new embolic spherical particle (HepaSphere) in a kidney animal model. Cardiovasc Intervent Radiol 31:367–376PubMedCrossRef
23.
Jiaqi Y, Hori S, Minamitani K et al (1996) A new embolic material: super absorbent polymer (SAP) microsphere and its embolic effects. Nippon Igaku Hoshasen Gakkai Zasshi 56:19–24PubMed
24.
Osuga K, Hori S, Hiraishi K et al (2008) Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc Intervent Radiol 31:1108–1116PubMedCrossRef
25.
Jordan O, Denys A, De Baere T et al (2010) Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21(7):1084–1090PubMedCrossRef
26.
Lee KH, Liapi EA, Cornell C et al (2010) Doxorubicin-loaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 33(3):576–582PubMedCrossRef
27.
Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173:83–91PubMedCrossRef
28.
29.
Geschwind JF, Ko YH, Torbenson MS et al (2002) Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62:3909–3913PubMed
30.
Furuta T, Kanematsu T, Kakizoe S et al (1983) Selective effect of doxorubicin suspended in lipiodol on VX2 carcinoma in rabbits. J Surg Oncol 39:229–234CrossRef
31.
Iwai K, Maeda H, Konno T et al (1987) Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res 7:321–327PubMed
32.
Nagamitsu A, Konno T, Oda T et al (1993) Targeted cancer chemotherapy for VX2 tumour implanted in the colon with lipiodol as a carrier. Eur J Cancer 34:1764–1769CrossRef
33.
Kan Z (1994) Iodized oil injected in the hepatic artery will enter the portal vein. J Vasc Interv Radiol 5:525–526PubMedCrossRef
34.
Kan Z (1996) Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. An experimental investigation in several animal species. Acta Radiol Suppl 408:1–25PubMed
35.
Kan Z, Sato M, Ivancev K et al (1993) Distribution and effect of iodized poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 186:861–866PubMed
36.
Kan Z, Wright K, Wallace S (1997) Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad Radiol 4(4):275–282PubMedCrossRef
37.
Nakamura H, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 170:783–786PubMed
38.
Olivi A, Brem H (1994) Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas. Recent Results Cancer Res 135:149–154PubMedCrossRef
39.
Osuga K, Hori S, Kitayoshi H et al (2002) Embolization of high flow arteriovenous malformations: experience with use of superabsorbent polymer microspheres. J Vasc Interv Radiol 13:1125–1133PubMedCrossRef
40.
Osuga K, Khankan AA, Hori S et al (2002) Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. J Vasc Interv Radiol 13:929–934PubMedCrossRef
41.
Stampfl S, Stampfl U, Rehnitz C et al (2007) Experimental evaluation of early and long-term effects of microparticle embolization in two different mini-pig models. Part II: liver. Cardiovasc Intervent Radiol 30:462–468PubMedCrossRef
42.
Siskin GP, Dowling K, Virmani R et al (2003) Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 14:89–98PubMedCrossRef
43.
Derdeyn CP, Graves VB, Salamat MS et al (1997) Collagen-coated acrylic microspheres for embolotherapy: in vivo and in vitro characteristics. AJNR Am J Neuroradiol 18:647–653PubMed
Metadata
Title
Hepatic Arterial Embolization with Doxorubicin-Loaded Superabsorbent Polymer Microspheres in a Rabbit Liver Tumor Model
Authors
Sanjay Gupta
Kenneth C. Wright
Joe Ensor
Carolyn S. Van Pelt
Katherine A. Dixon
Vikas Kundra
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
CardioVascular and Interventional Radiology / Issue 5/2011
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-011-0154-6

Other articles of this Issue 5/2011

CardioVascular and Interventional Radiology 5/2011 Go to the issue

Clinical Investigation

Changes in Normal Liver and Spleen Volume after Radioembolization with 90Y-Resin Microspheres in Metastatic Breast Cancer Patients: Findings and Clinical Significance

Letter to the Editor

Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis: Fact or Fiction!?

Clinical Investigation

Lung Tumors Treated With Percutaneous Radiofrequency Ablation: Computed Tomography Imaging Follow-Up

Clinical Investigation

Use of PTFE Stent Grafts for Hemodialysis-related Central Venous Occlusions: Intermediate-Term Results

Clinical Investigation

Kummel Disease Treatment by Unipedicular Vertebral Augmentation Using Curved Injection Cannula

Letter to the Editor

Endovascular Treatment of a Real Inferior Gluteal Artery Aneurysm Associated with a Pelvic Arteriovenous Malformation